Verastem, Inc.
NASDAQ:VSTMBiotechnology
-$0.00 today
- Market cap
- $865.72M
- Beta
- 0.27
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.97
Volume 3.97M
Average 2.58M
VSTM Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Verastem, Inc.NASDAQ: VSTM
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital turns negative
Q1 FY2026 change in working capital was -$8.57M, compared with $4.27M a year earlier. Trailing-twelve-month change in working capital was $13.17M. Over 3 fiscal years it compounded at +88.2% a year.
Context
- Change in working capital amounted to 84.1% of revenue in FY2025, up 46.9 pp from a year earlier.
- Change in working capital increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly change in working capital holds near -$8.57M or moves back toward the trailing-twelve-month quarterly average of $3.29M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 26M USD
- Year-over-year change
- +599.4%
- 4-year CAGR
- +158.3%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26M | +599.4% |
| FY2024 | 2024-12-31 | 3.72M | +488.5% |
| FY2023 | 2023-12-31 | (957K) | -124.5% |
| FY2022 | 2022-12-31 | 3.9M | +567.8% |
| FY2021 | 2021-12-31 | 584K | — |
Change in Working Capital vs competitors
How VSTM compares with its peers on the latest reported figures
- VSTM's LTM Mar 2026 change in working capital of $13.17M is the 4th largest of the 11 companies compared; the peer median is $2.31M.
- Its year-over-year change of +39.2% is the 3rd highest of 10, against a peer median of -13.9%.
- Change in working capital amounts to 26.6% of revenue for VSTM, versus a peer median of 110.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $31.04M | -3.9% | — | 110.0% | |
| LTM Mar 2026 | $23.74M | +149.1% | +20.4% | 68.1% | |
| LTM Mar 2026 | $21.6M | +725.2% | +212.4% | 129.2% | |
| LTM Mar 2026 | $13.17M | +39.2% | +88.2% | 26.6% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $10.61M | -10.2% | — | — |
| LTM Jun 2024 | $7.18M | — | — | 110.6% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $3.08M | -227.9% | +16.6% | — |
| LTM Jun 2026 | $2.95M | -350.5% | +51.5% | 1.7% | |
| LTM Mar 2026 | $1.66M | -293.7% | +30.6% | — | |
| LTM Mar 2026 | $994K | -13.9% | — | 189.3% | |
| LTM Mar 2026 | $974K | -159.1% | +130.6% | — | |
| Peer median (excluding VSTM) | $2.31M | -13.9% | +41.0% | 110.3% | |
Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.2M) | (73.81M) | (87.37M) | (130.64M) | (209.47M) |
| Depreciation & Amortization | 72K | (36K) | 62K | 26K | 728K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.71M | 6.05M | 5.86M | 7.34M | 9.4M |
| Change in Working Capital | 584K | 3.9M | (957K) | 3.72M | 26M |
| Accounts Receivables | (277K) | 485K | 31K | (200K) | (8.81M) |
| Inventory | 0 | 0 | 0 | 0 | (1.83M) |
| Accounts Payables | 623K | 2.6M | 2.28M | (3.16M) | 8.42M |
| Other Working Capital | 238K | 816K | (3.27M) | 7.08M | 28.23M |
| Other Non-Cash Items | 9.33M | 228K | (4.06M) | 14.78M | 35.83M |
| Operating Cash Flow | (53.5M) | (63.67M) | (86.46M) | (104.77M) | (137.51M) |
| Capital Expenditures | (196K) | 0 | 0 | (28K) | 0 |
| Acquisitions (Net) | 9.33M | 0 | 0 | 0 | 0 |
| Purchases of Investments | (86.44M) | (17.82M) | (96.45M) | 0 | 0 |
| Sales of Investments | 86.73M | 84M | 52M | 60M | 29K |
| Other Investing Activities | (9.33M) | 0 | 0 | 5K | (29K) |
| Investing Cash Flow | 87K | 66.19M | (44.45M) | 59.97M | (9.62M) |
| Debt Repayment | 0 | 24.15M | 14.62M | (150K) | 32.42M |
| Common Stock Issued | 6.72M | 27.35M | 91.42M | 14.22M | 230.88M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 162K | 282K | 57K | 40.71M | 0 |
| Financing Cash Flow | 6.89M | 51.78M | 134.19M | 54.78M | 263.31M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (46.53M) | 54.3M | 3.29M | 9.98M | 116.17M |
| Free Cash Flow | (53.7M) | (63.67M) | (86.46M) | (104.8M) | (137.51M) |
Verastem, Inc.
NASDAQ:VSTM
Intrinsic Alpha fair value
Locked
Current Price
$6.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.